Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?

8 Sept 2021

Abstract excerpt

Favipiravir is a novel broad-spectrum antiviral drug against RNA viruses that has been approved for the treatment of seasonal and pandemic influenza. The use of favipiravir is a potential therapeutic approach to SARS-CoV-2 infection; several clinical trials have shown that favipiravir could effectively improve the clinical recovery and/or viral RNA clearance of patients, with proven safety profiles.1,2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Respiratory viral infections research
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34518821
DOI: 10.1016/j.xinn.2021.100165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?PMID 34518821Read ↗

Structural basis of SARS-CoV-2 polymerase inhibition by FavipiravirSemantic proximity Read ↗

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In SilicoSemantic proximity Read ↗

Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infectionSemantic proximity Read ↗

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesisSemantic proximity Read ↗

Substrate and target selectivity of 4′-fluoroadenosine against viral and host polymerasesSemantic proximity Read ↗

Remdesivir for the treatment of Covid-19: the value of biochemical studiesSemantic proximity Read ↗

Nucleotide Analogues as Inhibitors of SARS-CoV‑2 Polymerase, a Key Drug Target for COVID-19Semantic proximity Read ↗

Unveiling the “Template-Dependent” Inhibition on the Viral Transcription of SARS-CoV-2Semantic proximity Read ↗

Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.Semantic proximity Read ↗

Lethal Mutagenesis of Rift Valley Fever Virus Induced by FavipiravirSemantic proximity Read ↗

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.Semantic proximity Read ↗

Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.